Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesTransdermal Nitroglycerin Therapy May Not Prevent Early Postmenopausal Bone Loss
Journal of Clinical Endocrinology and Metabolism, 07/01/09
Wimalawansa SJ et al. - BMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison to a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was -16 mg/day).
Sunil J. Wimalawansam, MD, PhD, MBA, 08/02/09
| This single center, three-year double-blind, randomized, clinical study in 188 early postmenopausal subjects, half received 22.5 mg of transdermal nitroglycerin (average dose ~16 mg/day) plus calcium plus vitamin D, while the control group received a placebo ointment, calcium and vitamin D. The primary endpoint, the lumbar spine BMD did not differ significant; under dosing of subjects was the primary reason for this. Taken together with other studies, we believe that higher dosages would not only preserve BMD, but may also improve fracture rates. If this is proven the case, nitric oxide donors are likely to be the most cost-effective therapy for prevention and treatment of osteoporosis. Hence, new studies are warranted in this fires of research. |
Today in Menopausal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Issues in postmenopausal hormone therapy: depression, endometrial health, and discontinuation
Sexuality, Reproduction & Menopause, 10/09/09
Testosterone supplementation: For whom and when?
Sexuality, Reproduction & Menopause, 10/08/09
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density
Journal of Bone and Mineral Research, 10/30/09
Sponsor
Article Search
Sponsor